Monday, 17 Feb 2020

Biotechs That Successfully Combat Cancer Could See Blockbuster Returns

NEW YORK: Gene therapy is hot on the trail of killing cancer, and companies that deliver cures could see blockbuster returns.

Pioneering a new paradigm in cancer therapeutics, Genprex Inc. (NASDAQGNPX) (GNPX Profile) is leveraging its patented technology platform to deliver powerful tumor-suppressing genes directly into cancer cells. Calithera Biosciences Inc. (NASDAQCALA) is looking for cures for cancer and other life-threatening diseases by discovering, developing and commercializing novel, small-molecule drugs that target tumor and immune cell metabolism. Adaptimmune Therapeutics plc (NASDAQADAP) is developing novel cancer immunotherapy products for cancer patients by engineering T-cells to target and destroy cancer. Agenus Inc. (NASDAQAGEN) is working on the discovery and development of therapies that engage the body's immune system to fight cancer by pursuing combination approaches that leverage a broad range of antibody therapeutics, proprietary cancer vaccine platforms and adoptive cell therapies. G1 Therapeutics Inc. (NASDAQGTHX) is advancing three clinical-stage programs designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications.

Cancer remains one of the most frustratingly difficult diseases to cure.
New gene-based therapeutic paradigms are now in play.
With breakthrough technologies, gene therapy is on the cusp of curing the incurable.
Biotech companies that deliver these cures could also deliver blockbuster returns.

(PRN | 8 months ago)